Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases

BACKGROUND: The development of a clinically useful fibroblast growth factor 21 (FGF21) hormone has been impeded by its inherent instability and weak FGF receptor (FGFR) binding affinity. There is an urgent need for innovative approaches to overcome these limitations. METHODS: We devised a structure-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Longwei, Niu, Jianlou, Lin, Huan, Zhao, Jing, Liu, Yang, Song, Zihui, Xiang, Congshang, Wang, Xiaojie, Yang, Yong, Li, Xiaokun, Mohammadi, Moosa, Huang, Zhifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838362/
https://www.ncbi.nlm.nih.gov/pubmed/31631034
http://dx.doi.org/10.1016/j.ebiom.2019.09.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838362/
https://www.ncbi.nlm.nih.gov/pubmed/31631034
http://dx.doi.org/10.1016/j.ebiom.2019.09.052

Ejemplares similares